This company has been marked as potentially delisted and may not be actively trading. Amryt Pharma (AMYT) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Alembic Pharmaceuticals Ltd.October 13, 2023 | wsj.comAMYT Historical DataOctober 10, 2023 | investing.comBeijing Sun-Novo Pharmaceutical Research Co. Ltd. AJuly 28, 2023 | wsj.comTrading was temporarily halted for "AMYT" at 07:04 PM with a stated reason of "News pending."April 12, 2023 | marketbeat.com2022 for Chiesi: The Group’s international growth continuesApril 11, 2023 | finance.yahoo.comHigh Court of Justice of England and Wales Sanctions Scheme of ArrangementApril 3, 2023 | finance.yahoo.comClear Harbor Asset Management LLC Sells 13,573 Shares of Amryt Pharma plc (NASDAQ:AMYT)Clear Harbor Asset Management LLC lowered its holdings in shares of Amryt Pharma plc (NASDAQ:AMYT - Get Rating) by 15.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 74,843 shares of the company's stockMarch 30, 2023 | marketbeat.comAmryt Pharma Stock (NASDAQ:AMYT), DividendsMarch 17, 2023 | benzinga.comAmryt Pharma plc (NASDAQ:AMYT) Sees Significant Decline in Short InterestAmryt Pharma plc (NASDAQ:AMYT - Get Rating) saw a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 52,600 shares, a drop of 6.9% from the January 31st total of 56,500 shares. Based on an average daily trading volume, of 570,900 shares, the short-interest ratio is currently 0.1 days.March 6, 2023 | marketbeat.comArmistice Capital LLC Purchases 94,000 Shares of Amryt Pharma plc (NASDAQ:AMYT)Armistice Capital LLC lifted its position in shares of Amryt Pharma plc (NASDAQ:AMYT - Get Rating) by 8.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,272,000 shares of the company's stock after puFebruary 24, 2023 | marketbeat.comAMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023February 16, 2023 | finance.yahoo.comAmryt Pharma Sees Unusually High Options Volume (NASDAQ:AMYT)Amryt Pharma plc (NASDAQ:AMYT - Get Rating) was the recipient of unusually large options trading activity on Friday. Stock investors acquired 6,003 put options on the stock. This is an increase of 1,596% compared to the average volume of 354 put options.January 13, 2023 | marketbeat.comAmryt Pharma (NASDAQ:AMYT) Receives Hold Rating from Canaccord Genuity GroupCanaccord Genuity Group restated a "hold" rating and issued a $17.00 price objective (down from $19.00) on shares of Amryt Pharma in a research note on Tuesday.January 10, 2023 | marketbeat.comAmryt Pharma's (AMYT) "Market Perform" Rating Reaffirmed at SVB LeerinkSVB Leerink reiterated a "market perform" rating and set a $14.50 price target (down previously from $19.00) on shares of Amryt Pharma in a report on Monday.January 9, 2023 | marketbeat.comWhy CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving PremarketJanuary 9, 2023 | msn.comEuropean drugmakers including AstraZeneca pony up for U.S.-listed biopharmasJanuary 9, 2023 | msn.comMaxim Group Reaffirms Their Buy Rating on Amryt Pharma (AMYT)January 6, 2023 | markets.businessinsider.comAmryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFHJanuary 5, 2023 | finance.yahoo.comAmryt Pharma plc (NASDAQ:AMYT) Sees Significant Decrease in Short InterestAmryt Pharma plc (NASDAQ:AMYT - Get Rating) was the target of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 68,700 shares, a decrease of 22.0% from the November 15th total of 88,100 shares. Based on an average trading volume of 35,300 shares, the short-interest ratio is presently 1.9 days.December 16, 2022 | marketbeat.comShort Interest in Amryt Pharma plc (NASDAQ:AMYT) Decreases By 15.2%December 2, 2022 | marketbeat.comAmryt Pharma plc (NASDAQ:AMYT) Sees Significant Growth in Short InterestAmryt Pharma plc (NASDAQ:AMYT - Get Rating) saw a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 103,900 shares, a growth of 19.6% from the October 15th total of 86,900 shares. Based on an average daily trading volume, of 30,400 shares, the short-interest ratio is currently 3.4 days.November 13, 2022 | marketbeat.comSVB Securities Keeps Their Buy Rating on Amryt Pharma (AMYT)November 7, 2022 | markets.businessinsider.comAmryt Pharma PLC (AMYT) Q3 2022 Earnings Call TranscriptNovember 6, 2022 | seekingalpha.comAmryt Reports Q3 2022 Financial and Operational ResultsNovember 3, 2022 | finance.yahoo.comLigand Pharmaceuticals (LGND) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOctober 31, 2022 | msn.comAmryt Pharma PLC Sponsored ADR (AMYT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOctober 27, 2022 | finance.yahoo.comQ3 2022 EPS Estimates for Amryt Pharma plc Reduced by SVB Leerink (NASDAQ:AMYT)Amryt Pharma plc (NASDAQ:AMYT - Get Rating) - Equities research analysts at SVB Leerink cut their Q3 2022 earnings per share estimates for shares of Amryt Pharma in a report released on Monday, October 24th. SVB Leerink analyst M. Foroohar now anticipates that the company will earn ($0.02) per shOctober 27, 2022 | marketbeat.comAmryt Pharma (AMYT) Set to Announce Quarterly Earnings on ThursdayAmryt Pharma (NASDAQ:AMYT) will be releasing earnings before the market opens on Thursday, November 3, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=481867)October 27, 2022 | marketbeat.comThe British Journal of Dermatology Publishes Results from Amryt’s EASE Phase 3 Trial in Epidermolysis BullosaOctober 25, 2022 | finance.yahoo.comAmryt Supports Global EB Awareness Week 2022October 24, 2022 | finance.yahoo.comAmryt to Report Q3 2022 Results on November 3, 2022October 19, 2022 | finance.yahoo.comShort Interest in Amryt Pharma plc (NASDAQ:AMYT) Rises By 17.0%Amryt Pharma plc (NASDAQ:AMYT - Get Rating) saw a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 89,500 shares, an increase of 17.0% from the September 15th total of 76,500 shares. Based on an average daily trading volume, of 42,600 shares, the short-interest ratio is currently 2.1 days.October 16, 2022 | marketbeat.comShort Interest in Amryt Pharma plc (NASDAQ:AMYT) Decreases By 16.9%Amryt Pharma plc (NASDAQ:AMYT - Get Rating) was the recipient of a significant decrease in short interest in September. As of September 15th, there was short interest totalling 76,500 shares, a decrease of 16.9% from the August 31st total of 92,100 shares. Based on an average daily volume of 56,700 shares, the short-interest ratio is currently 1.3 days.September 30, 2022 | marketbeat.comAmryt Supports FH Awareness Day – September 24, 2022September 23, 2022 | finance.yahoo.comAmryt Pharma Gets CHMP Backing for Mycapssa in Acromegaly >AMYTSeptember 16, 2022 | marketwatch.comCHMP adopts positive opinion for Mycapssa® for the treatment of AcromegalySeptember 16, 2022 | finance.yahoo.comAmryt Secures UK Regulatory Nod And Orphan Disease Status For Skin Disorder CandidateSeptember 8, 2022 | msn.comAmryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez® in Great BritainSeptember 8, 2022 | finance.yahoo.comAmryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022September 7, 2022 | finance.yahoo.comAmryt Pharma's (AMYT) Buy Rating Reiterated at Canaccord Genuity GroupCanaccord Genuity Group reaffirmed a "buy" rating and issued a $19.00 price target on shares of Amryt Pharma in a research note on Tuesday.September 6, 2022 | marketbeat.comAmryt Pharma (NASDAQ:AMYT) Rating Reiterated by HC WainwrightHC Wainwright reissued a "buy" rating on shares of Amryt Pharma in a research report on Monday.August 10, 2022 | marketbeat.comCan Amryt Pharma PLC Sponsored ADR (AMYT) Climb 187% to Reach the Level Wall Street Analysts Expect?August 9, 2022 | finance.yahoo.comAmryt Reports Record Q2 2022 ResultsAugust 4, 2022 | finance.yahoo.comShort Interest in Amryt Pharma plc (NASDAQ:AMYT) Increases By 24.6%Amryt Pharma plc (NASDAQ:AMYT - Get Rating) was the recipient of a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 102,700 shares, a growth of 24.6% from the June 30th total of 82,400 shares. Based on an average daily volume of 84,200 shares, the short-interest ratio is currently 1.2 days.August 2, 2022 | marketbeat.comAmryt to Report Q2 2022 Results on August 4, 2022July 21, 2022 | finance.yahoo.comAmryt Shares Shoot Higher As FDA Grants Orphan Drug Status To Carcinoid Tumor CandidateJuly 14, 2022 | markets.businessinsider.comAmryt Gets FDA Orphan Designation for Mycapssa in Carcinoid Syndrome >AMYTJuly 14, 2022 | marketwatch.comAmryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid SyndromeJuly 14, 2022 | finance.yahoo.comAmryt Presents New Analyses from the EASE Phase 3 Trial in Epidermolysis Bullosa at SPD 2022July 7, 2022 | finance.yahoo.comAmryt Announces Appointment of Dr Tracy Cunningham as Chief Medical OfficerJune 27, 2022 | finance.yahoo.com Get Amryt Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AMYT and its competitors with MarketBeat's FREE daily newsletter. Email Address AMYT Media Mentions By Week AMYT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMYT News Sentiment▼0.000.58▲Average Medical News Sentiment AMYT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMYT Articles This Week▼00▲AMYT Articles Average Week Get Amryt Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AMYT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PTCT News PRGO News ZLAB News RARE News RNA News AKRO News MRUS News PTGX News MOR News OGN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AMYT) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amryt Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Amryt Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
